NasdaqGS - Nasdaq Real Time Price USD

Myriad Genetics, Inc. (MYGN)

Compare

14.83

+0.05

+(0.34%)

At close: January 10 at 4:00:02 PM EST

14.83

0.00

(0.00%)

After hours: January 10 at 5:18:10 PM EST

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.

Zacks 2 days ago

MYGN
+0.34%
RMD
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and industry-leading hereditary canc

GlobeNewswire 3 days ago

MYGN
+0.34%
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the

GlobeNewswire 4 days ago

MYGN
+0.34%
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will

GlobeNewswire 4 days ago

MYGN
+0.34%
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies

GlobeNewswire 5 days ago

MYGN
+0.34%
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry. “Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Gene

GlobeNewswire 6 days ago

MYGN
+0.34%
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

Key Insights Myriad Genetics' estimated fair value is US$26.88 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. 19 days ago

MYGN
+0.34%
MYGN Stock Might Gain From the New Recognition of RiskScore Study

The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.

Zacks 23 days ago

MYGN
+0.34%
HAE
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick ModelSALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by

GlobeNewswire 24 days ago

MYGN
+0.34%
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.

Zacks 26 days ago

MYGN
+0.34%
HAE

BSX
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. Since the announcement, Myriad has ac

GlobeNewswire last month

MYGN
+0.34%
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Board from eight to nine members. Additionally, Davis was also appointed to the Audit and Finance Committee of Myriad’s Board. Davis is the Senior Relationship and Growth Advisor for Cross Country Consulting. Previously, Davis enjoyed a distinguished caree

GlobeNewswire last month

MYGN
+0.34%
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric SolutionsSALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network (NCCN®) as the guidelines underscore the critical role of the company’s portfolio of offerings across the patient’s prostate cancer jou

GlobeNewswire last month

MYGN
+0.34%
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.

Zacks last month

MYGN
+0.34%
HAE
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combin

GlobeNewswire last month

MYGN
+0.34%
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network (NCCN®) as an ‘Advanced Tool’ in the fight against prostate cancer1. Like other gene expression-based tests, Prolaris for many years has been

GlobeNewswire last month

MYGN
+0.34%
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.

Zacks last month

ILMN

MYGN
+0.34%
GMED
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor typesSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Re

GlobeNewswire last month

ILMN

MYGN
+0.34%
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. “Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would as

GlobeNewswire last month

MYGN
+0.34%
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $21 from $32 and keeps an Equal Weight rating on the shares. Q3 results came in slightly above the preliminary view as average selling price strength more than offset some volume softness, the analyst noted. UnitedHealth’s (UNH) decision to drop coverage of multi-gene behavioral health PGx tests equates annually to about $40M in revenue and about $30M in gross profit impact, notes the analyst, who adds that “broader payo

TipRanks last month

MYGN
+0.34%
UNH

Performance Overview

Return	MYGN	S&P 500
YTD	+8.80%	-1.35%
1-Year	-17.98%	+22.51%
3-Year	-40.51%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Myriad Genetics, Inc. (MYGN)

MYGN Stock Gains Following Collaboration With Hannah Storm

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price

MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley

Performance Overview